CM-101
Systemic Sclerosis
Key Facts
About Chemomab Therapeutics
Chemomab Therapeutics' mission is to develop first-in-class antibody therapies targeting the CCL24 pathway to halt fibrosis and inflammation in diseases with significant unmet need. Its key achievement is the advancement of its lead asset, CM-101, into mid-stage clinical trials for three distinct fibrotic indications. The company's strategy is to generate compelling Phase 2 proof-of-concept data to validate CCL24 as a therapeutic target and attract partnership or further development capital. As a micro-cap public company, its near-term fate is tightly coupled to the binary outcomes of these clinical readouts.
View full company profileAbout Chemomab Therapeutics
Chemomab Therapeutics' mission is to develop first-in-class antibody therapies targeting the CCL24 pathway to halt fibrosis and inflammation in diseases with significant unmet need. Its key achievement is the advancement of its lead asset, CM-101, into mid-stage clinical trials for three distinct fibrotic indications. The company's strategy is to generate compelling Phase 2 proof-of-concept data to validate CCL24 as a therapeutic target and attract partnership or further development capital. As a micro-cap public company, its near-term fate is tightly coupled to the binary outcomes of these clinical readouts.
View full company profileAbout Chemomab Therapeutics
Chemomab Therapeutics' mission is to develop first-in-class antibody therapies targeting the CCL24 pathway to halt fibrosis and inflammation in diseases with significant unmet need. Its key achievement is the advancement of its lead asset, CM-101, into mid-stage clinical trials for three distinct fibrotic indications. The company's strategy is to generate compelling Phase 2 proof-of-concept data to validate CCL24 as a therapeutic target and attract partnership or further development capital. As a micro-cap public company, its near-term fate is tightly coupled to the binary outcomes of these clinical readouts.
View full company profileTherapeutic Areas
Other Systemic Sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| Prostacyclin Analogue Program | Eicos Sciences | Pre-clinical |
| CellReady® for Systemic Sclerosis (A-MUSE Trial) | Cell-Easy | Phase 1/2 |
| Lanifibranor | Inventiva | Phase II |
| KYV-101 (mivocabtagene autoleucel) | Kyverna Therapeutics | Phase 1/2 |